Literature DB >> 7159689

Dose-dependent pharmacokinetics of furosemide in the rat.

M M Hammarlund, L K Paalzow.   

Abstract

The pharmacokinetics of furosemide were investigated in the rat at doses of 10 and 40 mg kg-1 corresponding to doses of 80 and 320 mg given to humans based on body surface area. A three-compartment open model with renal excretion taking place from the shallow peripheral compartment gave the best fit to the data. The terminal half-life of furosemide was found to change from 29 min for the 10 mg kg-1 dose to 49 min for the 40 mg kg-1 dose. This change could be detected as a change in the apparent volume of distribution caused by decreased protein binding at increasing plasma concentrations of furosemide. The total plasma clearance did not change significantly although metabolic and renal clearance both changed. The renal clearance was found to be dependent on the free fraction of furosemide in plasma and thus increased with increasing plasma concentrations. The metabolic clearance decreased with increasing dose indicating a saturable metabolism of furosemide.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7159689     DOI: 10.1002/bdd.2510030408

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  9 in total

Review 1.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

2.  Discrepancy between bioavailability as estimated from urinary recovery of frusemide and total diuretic effect.

Authors:  G Alván; G Paintaud; S A Eckernäs; A Grahnén
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

3.  Prophylactic furosemide to prevent transfusion-associated circulatory overload: a randomized controlled study in rats.

Authors:  Robert B Klanderman; Joachim J Bosboom; Denise P Veelo; Joris J T H Roelofs; Dirk de Korte; Robin van Bruggen; Liffert Vogt; Jaap D van Buul; Markus W Hollmann; Margreeth B Vroom; Nicole P Juffermans; Bart F Geerts; Alexander P J Vlaar
Journal:  Sci Rep       Date:  2022-07-15       Impact factor: 4.996

4.  Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism.

Authors:  M G Lee; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1983-12

5.  Urinary excretion and diuretic action of furosemide in rats: increased response to the urinary excretion rate of furosemide in rats with acute renal failure.

Authors:  T Kikkoji; A Kamiya; K Inui; R Hori
Journal:  Pharm Res       Date:  1988-11       Impact factor: 4.200

6.  Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis.

Authors:  M M Hammarlund; L K Paalzow; B Odlind
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition.

Authors:  S H Kim; Y M Choi; M G Lee
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

8.  Elucidation of the human serum albumin (HSA) binding site for the Cu-PTSM and Cu-ATSM radiopharmaceuticals.

Authors:  Nathan E Basken; Carla J Mathias; Mark A Green
Journal:  J Pharm Sci       Date:  2009-06       Impact factor: 3.534

9.  Topiramate is more effective than acetazolamide at lowering intracranial pressure.

Authors:  William J Scotton; Hannah F Botfield; Connar Sj Westgate; James L Mitchell; Andreas Yiangou; Maria S Uldall; Rigmor H Jensen; Alex J Sinclair
Journal:  Cephalalgia       Date:  2018-06-13       Impact factor: 6.292

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.